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Abstract (250 words) 
Because of the difficulty in detecting segment-specific response in the kidney, we 
investigated the molecular events underlying acute kidney injury in the proximal tubules 
of rats with cisplatin (cis-diamminedichloroplatinum II)-induced nephrotoxicity. 
Microarray analysis revealed that mRNA levels of several cytokines and chemokines, 
such as interleukin-1beta, chemokine (C-C motif) ligand (CCL) 2, CCL20, chemokine 
(C-X-C motif) ligand (CXCL) 1, and CXCL10 were significantly increased after 
cisplatin treatment in both isolated proximal tubules and whole kidney. Interestingly, 
tubular CCL2 mRNA levels increased soon after cisplatin administration, whereas 
CCL2 mRNA levels in whole kidney first decreased and then increased. Levels of both 
CCL2 and kidney injury molecule-1 (KIM-1) in the whole kidney increased after 
cisplatin administration. Immunofluorescence analysis revealed CCL2 changes in the 
proximal tubular cells initially and then in the medullary interstitium. Urinary CCL2 
excretion significantly increased approximately 3-fold compared with controls the day 
after cisplatin administration (5 mg/kg), when no changes were observed plasma 
creatinine and blood urea nitrogen levels. Urinary levels of KIM-1 also increased 3-fold 
after cisplatin administration. In addition, urinary CCL2 rather than KIM-1 increased in 
chronic renal failure rats after administration of low-dose cisplatin (2 mg/kg), 
suggesting that urinary CCL2 was selective for cisplatin-induced nephrotoxicity in renal 
impairment. These results indicated that the increase in cytokine and chemokine 
expression in renal epithelial cells might be responsible for kidney deterioration in 
cisplatin-induced nephrotoxicity, and that urinary CCL2 is associated with tubular 
injury and serves as a sensitive and noninvasive marker for the early detection of 
cisplatin-induced tubular injury. 
Manuscript number: BCP-D-12-01234 
Date of revision: December 12, 2012 
3 
Keywords 
acute kidney injury; microarray analysis; renal proximal tubule cells; monocyte 
chemotactic protein-1, MCP-1; kidney injury molecule-1, KIM-1 
 
Manuscript number: BCP-D-12-01234 
Date of revision: December 12, 2012 
4 
1. Introduction 
Avoiding renal injury is important in routine medical treatment because many 
nephrotoxic drugs can lead to tubular damage and result in acute kidney dysfunction [1]. 
Nephrotoxicity resulting from drug exposure has been estimated to contribute to 
19–25% of all cases of acute kidney injury in critically ill patients [2]. Ionic drugs are 
mainly secreted by tubular organic ion transporters across the luminal membranes of 
renal tubular epithelial cells after uptake from the blood by transporters in the 
basolateral membranes of the proximal tubules [3]. In addition, filtered and secreted 
toxins can be concentrated within the lumen of the tubule as fluid is reabsorbed. 
Therefore, proximal tubules are extraordinarily susceptible to drug-induced 
nephrotoxicity. The kidney is structurally complicated, consisting of many segments 
and cell types. Thus, it is difficult to investigate molecular events specific to a single 
nephron segment.  
Cisplatin (cis-diamminedichloroplatinum II) is one of the most effective 
chemotherapeutic agents against solid tumors, including testicular, head and neck, 
ovarian, and non-small cell lung cancers [4]. Despite its strong anti-tumor effects, 
severe nephrotoxicity limits clinical use. A basolateral organic cation transporter, OCT2 
(SLC22A2), mediates cisplatin transport from the circulation into proximal tubular 
epithelial cells, and renal proximal tubules are widely acknowledged to be major targets 
of cisplatin-induced nephropathy [5, 6]. Although several therapeutic strategies have 
been suggested for preventing cisplatin-induced renal injury, no effective treatments 
have been found aside from vigorous hydration [7]. In addition, a mechanism-based 
marker for detecting early cisplatin-induced proximal tubule injury has not been 
clinically developed. Creatinine and blood urea nitrogen levels increase significantly 
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only after substantial kidney injury occurs, and then after a significant time delay. Thus, 
monitoring the early responses of the proximal tubules to prevent further decline in 
renal function is important. 
We hypothesized that evaluating proximal tubule–specific changes would clarify the 
molecular mechanisms underlying cisplatin-induced nephrotoxicity and could lead to 
new markers for the detection of proximal tubule–specific injury. In the present study, 
we used microarray analyses of isolated proximal tubules. In addition to evaluating gene 
expression in the kidneys of rats with cisplatin-induced nephropathy, we measured 
urinary levels of chemokine (C-C motif) ligand (CCL) 2 (also known as monocyte 
chemotactic protein-1, MCP-1) and kidney injury molecule-1 (KIM-1) for potential use 
as markers for the early detection of cisplatin-induced nephropathy.
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2. Materials and Methods  
2.1. Animals  
Male Wistar/ST rats (8 weeks old) were purchased from SLC Animal Research 
Laboratories (Shizuoka, Japan). The rats were provided with a standard pelleted food 
and water ad libitum. Cisplatin (0.5 mg/mL; Randa
®
; Nippon Kayaku Co. Ltd., Tokyo, 
Japan) was administered intraperitoneally; the same volume of saline solution was 
injected into the sham controls. For microarray analysis, rats treated with 2 and 10 
mg/kg cisplatin 2 days after administration were used. For real-time PCR, 
immunofluorescence analysis, and measurements of urinary biomarkers, rats treated 
with 5 mg/kg cisplatin were used the next day, as well as 2, 4 and 7 days after 
administration, since more than half of the rats treated with 10 mg/kg of cisplatin died 
by the 4th day. Rats treated with the same volume of saline were used as Sham-treated 
rats. For the chronic renal failure model, cisplatin (2 mg/kg) or saline (vehicle) was 
administered on the 14th day after subtotal nephrectomy [8], and urine and blood 
samples were collected on days 1, 2, 4, and 7 after the administration of cisplatin or 
vehicle. Rats were maintained in metabolic cages for 24 h to determine urinary output 
levels and creatinine clearance. At time 0 and each day after cisplatin administration, 
plasma, bladder urine, and kidneys were collected. All the protocols were approved by 
the Animal Research Committee, Graduate School of Medicine, Kyoto University. 
 
2.2. Functional and histological examination of the kidneys  
Creatinine, blood urea nitrogen, and urinary albumin levels and the enzymatic 
activity of N-acetyl--D-glucosaminidase in bladder urine were measured as previously 
described [9]. For histological examination, kidneys were fixed in ethyl Carnoy’s 
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solution and stained with periodic acid-Schiff reagent (Sapporo General Pathology 
Laboratory Co. Ltd., Hokkaido, Japan). 
 
2.3. Isolation of renal proximal tubules via microdissection  
Microdissection was performed as previously reported [8, 10]. Briefly, rats were 
anesthetized with sodium pentobarbital (50 mg/kg intraperitoneally). The abdominal 
aorta was ligated just above and just below the left renal artery. The left kidney was 
perfused with 10 mL solution A (130 mM NaCl, 5 mM KCl, 1 mM NaH2PO4, 1 mM 
MgSO4, 1 mM calcium lactate, 2 mM sodium acetate, 5.5 mM D-glucose, and 10 mM 
N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid, pH 7.4) through the abdominal 
aorta and then with 10 mL solution B. Solution B consisted of solution A with 1 mg/mL 
collagenase A (Roche Diagnostic GmbH, Mannheim, Germany), 1 mg/mL bovine serum 
albumin (Sigma-Aldrich, St. Louis, MA, USA), and 10 mM vanadyl ribonucleotide 
complex (VRC; New England BioLabs Inc., Ipswich, MA, USA). 
Kidney slices were cut along the corticomedullary axis and incubated in solution B 
for 30 min at 37°C under aeration with 100% O2. After a wash with ice-cold solution A, 
the samples were microdissected with needles under a stereomicroscope at 10°C in 
solution A1 (solution A containing 10 mM vanadyl ribonucleotide complex) to obtain 
proximal tubules from the superficial nephron. Twenty millimeters of each proximal 
tubule was used for total RNA extraction. Total RNA was extracted with an RNeasy 
Mini Kit (Qiagen GmbH, Hilden, Germany), concentrated through ethanol precipitation, 
and used for microarray or real-time polymerase chain reaction (PCR) analysis. 
 
2.4. Gene expression array system 
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Digoxigenin-labeled cRNA was generated from total RNA extracted from the 
proximal tubules or whole kidney using a chemiluminescent reverse transcription-in 
vitro transcription labeling kit (v2.0; Applied Biosystems, Foster City, CA, USA). Ten 
micrograms of labeled cRNA from each reverse transcription reaction was hybridized 
onto a Rat Genome Survey Microarray (Applied Biosystems) at 55°C for 16 h following 
manufacturer recommendations. Microarrays were analyzed using an ABI 1700 
Chemiluminescent Microarray Analyzer (Applied Biosystems). 
 
2.5. Gene expression data analysis 
The array contained 34,656 oligonucleotide probes, including 26,857 individual 
gene probes and more than 1000 control probes. Microarray signal data were analyzed 
using Spotfire® (TIBCO Software Inc. Palo Alto, CA). Expression values were 
normalized across the experiments with 50% percentile values from each experiment. 
Genes were defined as detectable based on recommendations from Applied Biosystems: 
a gene with a signal-to-noise ratio of >3.0 in 2 or 3 assays and a FLAG value of <5000 
was considered detectable. Normalized signal data were analyzed statistically with 
1-way analysis of variance. Probability (P) values of <0.05 were considered statistically 
significant. The microarray data were deposited in the National Center for 
Biotechnology Information Gene Expression Omnibus 
(http://www.ncbi.nlm.nih.gov/geo/) and are accessible through accession number 
GSE37133. 
 
2.6. Real time-PCR analysis using isolated proximal tubules and whole kidney 
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Total rat kidney RNA was extracted using a MagNA Pure LC RNA Isolation 
Kit-High Performance (Roche Diagnostic GmbH) according to manufacturer 
instructions. Total RNA from renal proximal tubules was isolated as described above. 
RNA was reverse-transcribed with random hexamers using Superscript II reverse 
transcriptase (Invitrogen part of Life Technologies Corp., Carlsbad, CA, USA) and 
digested with RNase H (Invitrogen). Real-time PCR was carried out with an ABI 
PRISM 7700 Sequence Detector (Applied Biosystems) according to manufacturer 
instructions in a total volume of 20 L containing 5 L reverse-transcribed cDNA, 1 
M forward and reverse primers, 0.2 M TaqMan probe, and 10 L TaqMan Universal 
PCR Master Mix (Applied Biosystems). Glyceraldehyde-3-phosphate dehydrogenase 
mRNA expression was measured as an internal control. mRNA quantification was 
performed as reported elsewhere [8]. 
 
2.7. Immunofluorescence analysis 
Animals were anesthetized and their kidneys were perfused through the abdominal 
aorta, first with saline containing 50 U/mL heparin and then with 4% paraformaldehyde 
in phosphate-buffered saline (PBS). Fixed tissues were embedded in Tissue-Tek
®
 OCT 
compound (Sakura Finetechnical, Tokyo, Japan) and frozen rapidly in liquid nitrogen. 
Sections (5 m thick) were cut, permeabilized with 0.3% Triton X-100 in PBS for 30 
min, and incubated at 37°C for 60 min covered with goat serum (Wako, Osaka, Japan) 
for detecting CCL2 or with 5% bovine serum albumin in PBS containing 0.3% Triton 
X-100 for detecting Kim-1, interleukin (IL)-1beta, CCL20, chemokine (C-X-C motif) 
ligand (CXCL) 1, and CXCL10. The covered sections were incubated with antisera 
specific for CCL2, CXCL10 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), 
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IL-1beta (R&D Systems Inc., Minneapolis, MN, USA), CCL20 (Abcam, Cambridge, 
UK), CXCL1 (LifeSpan Biosciences Inc., Seattle, WA, USA), or Kim-1 at 4°C 
overnight [9, 11]. After further washing with PBS, the sections were incubated with 
Alexa Fluor 546-labelled second antibody (Invitrogen), Alexa Fluor 488-labeled 
phalloidin (Invitrogen), and 4′,6-diamidino-2-phenylindole (Wako) at 37°C for 60 min. 
The sections were examined, and images were captured with a BZ-9000 (Keyence, 
Osaka, Japan). 
 
2.8. Measuring urinary, plasma, and kidney CCL2 and urinary KIM-1 levels 
An additional experiment was performed to obtain urine samples from rats treated 
with 5 mg/kg cisplatin [12]. Urine samples were collected directly from the bladder 
when the kidneys were harvested. Protease inhibitor cocktail (Nacalai Tesque Inc., 
Kyoto, Japan) and phosSTOP (Roche Diagnostic GmbH) were added, and the urine and 
kidney tissue was stored at –80°C. The lysate of kidney samples was prepared as 
described in another report [13]. Concentrations of urinary and plasma and kidney 
lysate CCL2 were measured using an enzyme-linked immunosorbent assay kit (rat 
MCP-1; Immuno-Biological Laboratories Co. Ltd., Gunma, Japan). CCL2 
concentrations were normalized to urinary creatinine concentration. Urinary and kidney 
lysate KIM-1 protein levels were measured using microsphere-based Luminex xMAP 




For the chronic renal failure model, 6-week-old rats were subtotally nephrectomized 
as described elsewhere [8, 9, 11]. In brief, the right kidney was removed, and the 
posterior and anterior apical segmental branches of the left renal artery were 
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individually ligated. Previously, we have reported that the plasma level of testosterone 
decreased after nephrectomy, and the renal expression level of OCT2 was markedly 
decreased with decreased renal distribution of cisplatin [5]. Therefore, testosterone 
enanthate (2.5 mg/mL corn oil) was subcutaneously administered to nephrectomised 
rats at a dose of 200 µL/body (0.5 mg/body) on the day of nephrectomy and on days 3, 
8, and 13 after nephrectomy to maintain the expression level of OCT2 and renal uptake 
of cisplatin [16].  
 
2.9. Statistical analyses 
Data are expressed as mean ± standard error. Data were analyzed statistically using 
the unpaired Student t test. Multiple comparisons were performed with Dunnett’s 
2-tailed test after 1-way analysis of variance. P values of <0.05 were considered 
statistically significant. 
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3. Results 
3.1. Comparison of gene expression profiles in isolated proximal tubules and whole 
kidneys  
Microarray analyses were carried out using total RNA samples isolated from 
microdissected proximal tubules and whole kidney. Of the 26,857 gene probes, 12,840 
and 10,915 were detected in the isolated proximal tubules and whole kidney, 
respectively. Of these, 8,206 genes were expressed in both tissue. We analyzed the 
expression of solute carrier (Slc) family genes to evaluate the specificity of the 
microarray assay in isolated tubules. Slc family genes are abundantly expressed in renal 
proximal tubules, and their distribution pattern across kidney segments has been 
determined. As shown in Table 1, expression levels of 23 of the 184 Slc genes differed 
by at least 5-fold between isolated tubules and whole kidney. Most of these genes 
(displaying a tubule : whole kidney signal ratio of >5:1) were expressed in the proximal 
convoluted tubules. However, 9 genes (displaying a tubule : whole kidney signal ratio 
of <1:5) were expressed not in the proximal convoluted tubules but in the proximal 
straight tubule, another kidney segment, or in an identified region. 
 
3.2. Microarray analysis of isolated proximal tubules from cisplatin-treated rats 
To clarify the effects of various cisplatin doses on gene expression profiles in renal 
proximal tubules, we treated rats with cisplatin, 2 mg/kg or 10 mg/kg. The biochemical 
parameters of the animals 2 days after cisplatin administration are shown in Table 2. 
Plasma creatinine and blood urea nitrogen levels and creatinine clearance were 
comparable between sham-treated rats and the rats treated with 2 mg/kg cisplatin, 
whereas urinary albumin excretion was slightly increased in the latter group. 
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Conversely, rats treated with 10 mg/kg cisplatin showed severe nephrotoxicity. Plasma 
creatinine and blood urea nitrogen levels significantly increased, and body weight and 
creatinine clearance markedly decreased after treatment at this dose. Urinary albumin 
excretion was also significantly increased compared to sham-treated rats and rats treated 
with 2 mg/kg cisplatin. 
Microarray analyses were performed on tubules isolated from sham- and 
cisplatin-treated rats. The gene numbers that changed significantly from the control 
were 311, 1961, and 1643 in the renal proximal tubules from rats treated with 2 and 10 
mg/kg cisplatin and whole kidney from rats treated with 10 mg/kg cisplatin, 
respectively. Only 8 genes were commonly changed in the all 3 groups. Scatter plots of 
the gene expression signals from the isolated proximal tubules (rats treated with 
cisplatin, 2 mg/kg and 10 mg/kg) and whole kidney (rats treated with 10 mg/kg 
cisplatin) showed that the expression changes in rats treated with 2 mg/kg cisplatin were 
moderate compared with those of rats given 10 mg/kg cisplatin in comparisons with 
data from sham-operated rats. Conversely, 10 mg/kg cisplatin induced severe changes in 
gene expression in both isolated tubules and whole kidney.  
 
3.3. Microarray analysis of the expression profile of signaling molecules  
We then focused on signal-transducing molecules, selecting the genes in the 
proximal tubules or whole kidney that changed significantly and more than 2-fold with 
cisplatin treatment. Table 3 shows the 59 signaling molecules detected with this analysis. 
Among these, cytokines and chemokines were frequently increased in rats treated with 
10 mg/kg cisplatin. The expression levels of 12 genes, including proinflammatory 
molecule IL-1beta and several chemokines (CCL2, CCL17, CCL19, CCL20, CXCL1, 
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CXCL2, CXCL10, and CXCL11) increased markedly (P < 0.05; >5-fold). Furthermore, 
the expression of 8 genes (Bmp4, Egf, Lect2, Nrg1, Plcl1, Ppp1r1a, Tspan5, 
LOC307992) significantly decreased to less than 20% of baseline (P < 0.05). 
 
3.4. Changes in cytokine and chemokine expression in the kidneys of cisplatin-treated 
rats  
Blood urea nitrogen and urinary albumin levels increased and creatinine clearance 
decreased in rats 4 days after treatment with 5 mg/kg cisplatin (Figure 1a). Furthermore, 
urinary N-acetyl--D-glucosaminidase activity increased the day after cisplatin 
administration. Histological analysis revealed few changes in the glomeruli, and 
moderate damage was observed in the proximal tubules 1 or 2 days after cisplatin 
administration (Figure 1b). Degeneration of tubular cells, demonstrated by brush border 
loss, tubular dilation, and cast formation, was most prominent 4 and 7 days 
post-treatment. These histological findings corresponded with changes in biochemical 
parameters, such as increased plasma creatinine and blood urea nitrogen levels.  
Real-time PCR analyses using reverse-transcribed DNA samples prepared from 
whole kidneys were carried out to examine the changes in cytokine and chemokine 
expression associated with cisplatin-induced nephrotoxicity. The expression levels of 
IL-1beta, CCL2, CCL20, CXCL1, and CXCL10 were significantly increased with 
cisplatin treatment and peaked 4–7 days after the administration of 5 mg/kg of the drug 
(Figure 2).  
 
3.5. Comparison of CCL2 and KIM-1 expression in the proximal tubules and whole 
kidney  
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The expression profiles of CCL2 and Kim-1 mRNA were compared in the isolated 
proximal tubules and whole kidney (Figures 3a and 3b). In whole-kidney samples, 
CCL2 mRNA levels decreased 1 and 2 days after treatment and then increased 4 and 7 
days after treatment. Conversely, CCL2 expression gradually increased in the tubules 
immediately after cisplatin administration (Figure 3a) and Kim-1 expression increased 
greatly in a time-dependent manner in both the whole kidney and the tubules (Figure 
3b). In addition, the expression profiles of CCL2 and KIM-1 proteins were compared 
(Figures 3c and 3d). In whole kidney lysate samples, CCL2 protein levels increased 
slightly 1 and 2 days after treatment and then peaked sharply 4 and 7 days after 
treatment (Figure 3c). KIM-1 protein expression was not detected at day 0, but it 
increased greatly by 7 days in a time-dependent manner (Figure 3d). 
 
3.6. Time-dependent changes in CCL2 and KIM-1 protein expression and intra-renal 
distribution in rats with cisplatin nephropathy 
Immunofluorescence analysis revealed CCL2 staining specifically in the cytoplasm 
of proximal tubules that was absent in the inner and outer medulla 1 and 2 days after 
cisplatin administration (Figure 4). CCL2 expression markedly increased in the 
proximal tubules, and strong CCL2 staining was observed in the interstitial region of the 
outer medulla on day 4. Furthermore, CCL2 expression decreased by day 7 in both the 
proximal tubules and the interstitial region of the outer medulla. No KIM-1 was 
detected in sham-treated rats (Figure 5). KIM-1 staining was observed in the apical 
membrane of proximal tubules in medulla at day 1 and 2, and KIM-1 expression 
decreased in a time-dependent manner and diffused to the superficial region. By day 7, 
the KIM-1 signal disappeared in the medulla and decreased in the cortex. 
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We also examined the localization of other cytokines and chemokines (Figure 6). 
Immunofluorescence signals for IL-1beta (Figure 6a), CCL20 (Figure 6b), CXCL1 
(Figure 6c), and CXCL10 (Figure 6d) were detected in the renal epithelial cells. The 
reproducibility of immunofluorescence analyses was confirmed using several different 
sections.  
 
3.7. Increase in urinary CCL2 and KIM-1 levels in normal rats treated with cisplatin 
Urinary CCL2 significantly increased the day after cisplatin administration to 
approximately 3 times that observed in sham-treated rats (Figure 7a). CCL2 levels 
further increased on day 2 and peaked on day 4. Measured urinary CCL2 excretion 
corresponded well with the results of mRNA and immunofluorescence analyses. 
However, plasma CCL2 levels remained constant in cisplatin-treated rats. Urinary 
KIM-1 levels also significantly increased the day after cisplatin administration and 
continued to rise with the deterioration of renal function (Figure 7b). Plasma creatinine 
and blood urea nitrogen levels increased significantly on day 4 but did not change on 
days 1 and 2 (Figure 7c). 
 
3.8. Increase in urinary CCL2 and KIM-1 levels in chronic renal failure rats treated 
with cisplatin 
Urinary CCL2 markedly increased the day after cisplatin administration to 
approximately 4 times that observed in vehicle-treated chronic renal failure rats (Figure 
8a). CCL2 levels increased further through day 7. Conversely, significant difference in 
plasma CCL2 level was observed between vehicle-treated and cisplatin-administered 
rats from days 2 to 7 (Figure 8b). Urinary KIM-1 levels in vehicle-treated chronic renal 
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failure rats gradually increased from days 4 to 7 with or without cisplatin administration 
(Figure 8c). Plasma creatinine and blood urea nitrogen levels did not significantly 
increase with or without cisplatin administration (Figure 8d). The renal expression level 
of OCT2 was similar between vehicle-treated and cisplatin-administered 
nephrectomized rats (data not shown).
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4. Discussion 
The renal proximal tubule is one of the kidney segments most susceptible to 
drug-induced injury because it concentrates numerous toxins [17]. In the present study, 
we successfully established an analytical system that focuses on gene expression in 
proximal tubules isolated by microdissection. As shown in Table 1, the signals of some 
Slc family transporters were higher in the proximal tubules than in whole kidney. The 
Na
+
/D-glucose cotransporter (SGLT2/Slc5a2) is reported to be specifically localized to 
the S1 segment of renal proximal tubules; accordingly, in our microarray analysis, the 
SGLT2 mRNA signal in the proximal tubules was much higher than that in whole 
kidney. Conversely, the signal for the amino acid transporter Slc7a12, which is 
localized at the collecting ducts in the cortex, outer medulla, and inner medulla, was 
very low in the proximal tubules. Thus, microarray analysis using viable isolated 
proximal tubules can specifically reveal gene expression patterns in the renal proximal 
tubules without contamination from other nephron segments and infiltrating immune 
cells. 
We have previously shown that renal cationic transporters determine the 
nephrotoxicity of cisplatin [5, 18, 19]. Cisplatin uptake, primarily by OCT2, and delay 
in tubular secretion by luminal H
+
/organic cation antiporter/multidrug and toxin 
extrusion (MATE/SLC47A) causes drug accumulation and subsequent cytotoxicity in 
the proximal tubules in rats and humans. Concomitant administration of imatinib and 
cisplatin prevents cisplatin nephrotoxicity by inhibiting its OCT2-mediated basolateral 
uptake, thus preventing tubular injury [20]. In the present study, we used microarray 
analyses to clarify the changes in expression of tubular damage–specific genes in rats 
with cisplatin-induced nephrotoxicity. Intraperitoneal cisplatin administration resulted 
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in dose-dependent nephrotoxicity [5]. Renal proximal tubules are the primary site of 
drug-induced injury, followed by glomerular damage in cisplatin-induced nephropathy. 
Consistent with our results (see Table 3), those of a study by Ramesh and Reeves [21] 
showed activation of proinflammatory cytokines and chemokines in the kidneys of 
cisplatin-treated mice. Thus, enhanced cytokine and chemokine expression in proximal 
tubular epithelial cells is a major feature of cisplatin tubular toxicity.  
To investigate time-dependent changes in the cytokines and chemokines, further 
experiments were conducted using rats treated with 5 mg/kg cisplatin, because of the 
poor survival of the rats treated with 10 mg/kg of cisplatin. Tubular injury became 
apparent earlier than a reduction in glomerular filtration rate in rats treated with 5 mg/kg 
cisplatin. Glomerular filtration rate reduction occurred on day 4, and renal function 
slightly improved on day 7. The mRNA expression profiles of IL-1beta, CCL2, CCL20, 
CXCL1, and CXCL10 were examined in the whole kidney to investigate the roles of 
cytokines and chemokines in the pathogenesis of cisplatin-induced nephrotoxicity (see 
Figure 2). The analysis revealed that the expression levels of these genes gradually 
increased 1–2 days after cisplatin treatment and peaked 4–7 days after treatment in 
parallel with the deterioration of renal function. A significant increase in CCL2 
expression was detected in the proximal tubules the day after cisplatin administration, 
although CCL2 levels did not significantly increase in the whole kidney samples at this 
time (see Figure 3a). CCL2 mRNA levels markedly increased in both the proximal 
tubules and the whole kidney as did CCL2 protein in the whole kidney samples at the 
same time that blood urea nitrogen levels significantly increased and creatinine 
clearance decreased (see Figures 1a, 2b, 3a and 3c). 
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To obtain more detailed information, we determined the renal distribution of CCL2 
protein through immunofluorescence analyses. CCL2 protein levels specifically and 
significantly increased in the tubular epithelium (see Figure 4). These results suggested 
that past studies using whole-kidney samples did not accurately detect segment-specific 
changes in CCL2 expression and missed early increases in CCL2 expression in the 
proximal tubules after cisplatin treatment. Furthermore, immunofluorescence analysis 
of other genes showed increases in IL-1beta, CCL20, CXCL1, and CXCL10 levels in 
tubular epithelial cells (see Figure 6) in agreement with the mRNA expression profiles 
of these proteins (see Figure 2), which were detected not only in the proximal tubules 
but also in the interstitial area of the medulla, suggesting that the proteins were secreted 
into the interstitium. These mediators may be essential factors for expanding immune 
cell–mediated renal inflammatory injury. There are numerous reports on the putative 
roles of CCL2 in renal diseases. CCL2 has been reported to be extensively involved in 
tubulointerstitial damage, including infiltration of monocytes and interstitial fibrosis in 
IgA nephropathy and diabetic nephropathy [22, 23]. Wada T at al. [24] showed that 
anti-CCL2 antibodies remarkably reduced glomerulosclerosis and improved renal 
dysfunction, as well as proteinuria in an animal model of crescentic glomerulonephritis, 
and similar renoprotective effects were observed in CCL2-depleted rats treated with the 
dominant negative gene of CCL2 [9]. Furthermore, the blockade of CCL2 signaling by 
CCR2 antagonist or CCR2 deletion showed a decrease in interstitial infiltrated 
macrophages in ischemia-reperfusion injury [25, 26]. Considering these reports, CCL2 
might contribute to the development of renal injury as an exacerbation factor. 
The expression of tumor necrosis factor (TNF)-alpha is reportedly important for the 
upstream regulation of proinflammatory cytokines [21, 27, 28]. Zhang et al. [29] have 
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shown that the production of TNF-alpha by renal parenchymal cells rather than by bone 
marrow–derived infiltrating immune cells is responsible for cisplatin-induced 
nephropathy. Although we found no increase in TNF-alpha mRNA in microarray 
analysis of isolated proximal tubules, the expression of several cytokines and 
chemokines markedly increased in renal epithelial cells. Taken together, these data 
suggest that renal epithelial cells may be an important source of several cytokines and 
chemokines that contribute to cisplatin-induced acute kidney injury.  
KIM-1 (also known as hepatitis A virus receptor 1, Havcr1, or T-cell 
immunoglobulin and mucin, Tim-1), is a type I transmembrane protein undetectable in 
normal kidney tissue. Its expression increases in injured proximal tubular epithelial cells 
after ischemic or toxic injury [15]. The ectodomain of KIM-1 is stable in urine and can 
be detected both in the urine of patients with acute kidney injury [30] and in a variety of 
animal models of nephropathy induced by cisplatin [31, 32], 
S-(1,1,2,2,-tetrafluoroethyl)-L-cysteine, folic acid [31], and cyclosporine [33]. Urinary 
Kim-1 levels are exceptionally low under normal conditions but are highly induced 
immediately after tubular damage. Increased urinary KIM-1 occurs before increases in 
the levels of plasma creatinine and blood urea nitrogen in post-ischemic kidneys [32] 
and after a large number of toxins are released [15].  
In the present study, renal mRNA expression and urinary excretion of KIM-1 were 
determined as references to evaluate the usefulness of examining CCL2 levels. 
Comparable to previous findings [31], Kim-1 mRNA and protein expression in the 
whole kidney samples and proximal tubules and KIM-1 urinary levels significantly 
increased the day after cisplatin administration (see Figures 3b, 3d, 5, and 7b). CCL2 
expression predominantly increased in the proximal tubules (see Figures 3a and 4), and 
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similar to that of KIM-1, CCL2 excretion in the urine increased 1 day after cisplatin 
treatment (see Figure 7a). Notably, KIM-1 and CCL2, which dominantly appeared in 
the proximal tubules and urine before changes in blood urea nitrogen levels and 
creatinine clearance, were observed after cisplatin treatment (see Figure 7c). Because 
CCL2 was detected with immunofluorescence analysis only in the proximal epithelial 
cells 1 and 2 days after cisplatin treatment, urinary CCL2 was derived from proximal 
tubular epithelial cells and reflected tubular injury. In addition, urinary CCL2 rather 
than KIM-1 increased for 7 days after low-dose administration of cisplatin (2 mg/kg) in 
subtotal nephrectomized rats, whereas plasma levels of CCL2, creatinine, and blood 
urea nitrogen were constant (see Figure 8). In progressive chronic renal failure rats, 
urinary levels of KIM-1 were rapidly increased by treatment of cisplatin, but its level 
also gradually increased without cisplatin treatment (see Figure 8c). Therefore, the 
additional increase of KIM-1 by cisplatin treatment was considered to be small, 
suggesting that urinary KIM-1 levels reflected the sum of cisplatin-induced 
nephrotoxicity and accumulating tubular damage by subtotal nephrectomy. On the other 
hand, urinary levels of CCL2 were supposed to be associated with the dosage of 
cisplatin (5 mg/kg in Figure 7a; 2 mg/kg in Figure 8a) regardless of subtotal 
nephrectomy. These results indicated that compared with urinary KIM-1, increased 
urinary CCL2 was relatively selective for cisplatin-induced nephrotoxicity, and 
therefore, expression of renal CCL2 might be induced in association with renal 
accumulation of cisplatin. Some reports have associated urinary CCL2 with some renal 
diseases. In patients with IgA nephropathy or lupus nephritis, urinary CCL2 is increased 
and related to disease stage [34-39]. In addition to its presence in these autoimmune 
diseases, CCL2 has been detected in the urine of patients with diabetic nephropathy [40] 
Manuscript number: BCP-D-12-01234 
Date of revision: December 12, 2012 
23 
and polycystic kidney disease [41]. Recently, urinary CCL2 has been identified as a 
marker of renal function decline in diabetic and nondiabetic proteinuric renal disease 
independent from and additive to proteinuria [42]. These reports suggest that CCL2 
might be associated with the pathogenesis of several kidney diseases and be a relatively 
stable biomarker in patient urine samples. Taken together, the combination of urinary 
CCL2 and Kim-1 may be a more sensitive and specific biomarker for cisplatin-induced 
nephrotoxicity, especially in patients with renal impairment. 
In conclusion, microarray analysis with isolated proximal tubules was useful to 
detect specific responses in intact proximal tubules after renal injury. Furthermore, 
increases in inflammatory cytokines and chemokines in the proximal tubules preceded 
kidney functional changes observed with the progression of cisplatin-induced 
nephropathy. Although further validation with clinical samples is needed, urinary CCL2 
and Kim-1 might be non-invasive biomarkers for detecting cisplatin-induced tubular 
toxicity in humans. 
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Table 1. Comparison of the solute carrier family expression levels in isolated proximal tubules and whole kidney. 
  Probe ID   
Gene 
Symbol 
  Ratio P value   RefSeqs Renal distribution Reference 
Proximal tubule > Whole kidney      
 20931266  Slc2a2  9.8  0.000   NM_012879.1 PCT [43] 
 21588487  Slc3a2  8.5  0.002   NM_019283.1 PCT (mouse) [44] 
 21943154  Slc4a4  50.5  0.001   NM_053424.1 PCT [45] 
 22386465  Slc5a2  491.3  0.000   NM_022590.2 PCT [46] 
 21957982  Slc6a8  5.9  0.029   XM_579415 N.A. - 
 20879733  Slc7a7  150.5  0.000   NM_031341.1 PCT (mouse) [47] 
 21509630  Slc7a9  15.2  0.003   NM_053929.1 PCT [48] 
 21041351  Slc9a3  6.2  0.000   XM_579341 PCT [49] 
 20742389  Slc12a8  11.0  0.000   NM_153625.1 N.A. - 
 21280496  Slc13a1  11.9  0.000   NM_031651.1 PCT [50] 
 20808386  Slc15a1  44.2  0.002   NM_057121.1 PCT [51] 
 21184793  Slc16a1  79.5  0.002   NM_012716.1 PCT (mouse) [52] 
 20744521  Slc16a6  18.1  0.043   NM_198760.1 N.A. - 
 21014572  Slc16a14  11.5  0.001   NM_001108229.1 N.A. - 
 21479059  Slc22a1  6.4  0.000   NM_012697.1 PCT [53] 
 21858745  Slc22a5  6.9  0.009   NM_019269.1 PCT [54] 
 20967193  Slc22a8  8.4  0.018   NM_031332.1 PCT [55] 
 22122470  Slc26a1  6.0  0.027   NM_022287.1 PCT [56] 
 21788690  Slc26a4  7.7  0.060   NM_019214.1 CCD [57] 
 20797965  Slc28a2  5.2  0.002   NM_031664.1 PCT, PST, OMCD [58] 
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 22191184  Slc30a2  8.6  0.008   NM_012890.1 N.A. - 
 22298458  Slc32a1  7.1  0.241   NM_031782.1 N.A. - 
 21770029  Slc34a3  8.0  0.000   NM_139338.1 PCT [59] 
           
Proximal tubule < Whole kidney      
 21160091  Slc4a11  0.087  0.113   XM_230605 IMCD [60] 
 22351360  Slc7a12  0.038  0.011   NM_001011948.1 CCD, OMCD, IMCD (mouse) [61] 
 21486326  Slc7a13  0.120  0.010   XM_575781 PST, DCT (mouse) [62] 
 21875597  Slc21a13  0.168  0.037   NM_130736.1 N.A. - 
 21666827  Slc22a19  0.147  0.012   XM_342011 PST [63] 
 21889439  Slc22a7  0.151  0.009   NM_053537.1 PST [64] 
 21624701  Slc23a3  0.142  0.041   XM_346061 N.A. - 
 21018836  Slc34a2  0.125  0.037   XM_579555 N.A. - 
  21451109   Slc41a2   0.164  0.122    NM_001108742.1 N.A. - 
The expression levels of solute carrier (Slc) family genes were examined and compared by microarray analysis. The ratios of proximal tubule:whole kidney mRNA 
expression levels are also presented. PCT, proximal convoluted tubule; CCD, cortical collecting duct; PST, proximal straight tubule; OMCD, outer medullary 
collecting duct; IMCD, inner medullary collecting duct; TAL, thick ascending limb; DCT, distal connecting tubule; N.A., not available. 
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Table 2. Biochemical parameters of cisplatin-treated rats.
a
 
    
Shamb 
  Cisplatin 
 Parameter  Units   2 mg/kg 10 mg/kg 
Body weight G 282 ± 4  279 ± 3 248 ± 4** 
Plasma creatinine mg/dL 0.52 ± 0.07  0.54 ± 0.04 0.90 ± 0.05** 
Creatinine clearance  ml/min 1.34 ± 0.15  1.50 ± 0.05 0.70 ± 0.08** 
Blood urea nitrogen mg/dL 14.4 ± 0.9  17.5 ± 0.1 46.6 ± 2.0** 
Albumin excretion mg/day 0.39 ± 0.11  0.81 ± 0.62* 9.67 ± 2.10* 
Blood and urine samples were obtained from cisplatin-treated rats 2 days after cisplatin administration. 
aEach value represents mean ± standard error; multiple comparisons were performed with Dunnett’s 2-tailed test after 1-way analysis of variance. bSham, 
vehicle-treated rats. *P < 0.05, **P < 0.01, significantly different from sham-treated rats. 
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Table 3. Changes in signaling molecule expression levels in cisplatin-treated rats.  
      Proximal tubule   Whole kidney     




Gene name Ratio P value   Ratio P value   Ratio P value   RefSeqs 
21531200 Abtb2 
Ankyrin repeat and BTB (POZ) domain 
containing 2 
1.03  0.8936   0.34  0.0062   0.34  0.0443   NM_134403.1 
21031514 Adm Adrenomedullin 1.04  0.9232   4.11  0.0326   6.93  0.0193   NM_012715.1 
21515889 Angptl4 Angiopoietin-like protein 4 0.54  0.6372   6.54  0.0185   11.69  0.0146   NM_199115.2 
21706219 Bcl2 B-cell leukemia/lymphoma 2 1.28  0.1133   0.29  0.0011   1.62  0.1996   NM_016993.1 
21567665 Bcl2l1 Bcl2-like 1 1.04  0.8814   0.34  0.0062   0.62  0.1152   NM_001033670.1 
22406016 Bcl2l2 Bcl2-like 2 1.81  0.1308   2.65  0.0162   4.42  0.0443   NM_021850.2 
21591819 Blnk B-cell linker 0.81  0.4571   2.94  0.0101   4.38  0.0106   NM_001025767.1 
21743176 Bmp2 Bone morphogenetic protein 2 2.66  0.0407   3.35  0.0149   2.60  0.1146   NM_017178.1 
20823942 Bmp4 Bone morphogenetic protein 4 2.10  0.0859   0.40  0.0838   0.08  0.0182   NM_012827.1 
20907835 Ccl2 Chemokine (C-C motif) ligand 2 2.60  0.2375   9.33  0.0047   3.36  0.0096   NM_031530.1 
22219977 Ccl17 
Small inducible cytokine subfamily A 
(Cys-Cys), member 17 
1.03  0.9591   1.22  0.5490   3.21  0.0041   NM_057151.1 
21438363 Ccl19 Chemokine (C-C motif) ligand 19 1.28  0.4879   7.07  0.0159   10.02  0.0211   XM_342824 
21035433 Ccl20 Chemokine (C-C motif) ligand 20 0.83  0.7799   25.34  0.0112   20.12  0.0034   NM_019233.1 
22317053 Cxcl1 Chemokine (C-X-C motif) ligand 1 2.32  0.2819   25.16  0.0211   5.19  0.0776   NM_030845.1 
20807096 Cxcl2 Chemokine (C-X-C motif) ligand 2 1.93  0.3376   5.50  0.0163   4.22  0.0093   NM_053647.1 
21382174 Cxcl10 Chemokine (C-X-C motif) ligand 10 0.45  0.5638   7.60  0.0494   12.08  0.0131   NM_139089.1 
21707155 Cxcl11 Chemokine (C-X-C motif) ligand 11 1.06  0.8853   6.48  0.0762   4.13  0.0438   NM_182952.2 
20983420 Dtr Diphtheria toxin receptor 1.46  0.3258   15.83  0.0155   10.18  0.0018   NM_012945.1 
21546114 Egf Epidermal growth factor 0.69  0.3589   0.19  0.0443   0.10  0.0157   NM_012842.1 
21186251 Elmo3 
Engulfment and cell motility 3, ced-12 
homolog (Caenorhabditis elegans) 
1.17  0.7562   1.02  0.9676   0.22  0.0042   NM_001030028.1 
21470303 Esm1 Endothelial cell-specific molecule 1 0.87  0.5572   0.88  0.6551   0.40  0.0263   NM_022604.2 
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21964976 Fgb Fibrinogen, B beta polypeptide 1.05  0.8336   18.78  0.0284   4.32  0.0373   NM_020071.1 
21518483 Fgf9 Fibroblast growth factor 9 1.54  0.0009   0.37  0.0040   0.51  0.0651   NM_012952.1 
21812027 Fgf13 Fibroblast growth factor 13 1.67  0.1527   0.46  0.0254   0.43  0.2588   NM_053428.1 
21487754 Fgf22 Fibroblast growth factor 22 0.60  0.2978   2.96  0.0209   0.73  0.0758   NM_130751.1 
21189934 Glg1 Golgi apparatus protein 1 1.04  0.8620   0.32  0.0140   0.51  0.0738   NM_017211.1 
21900160 Grb2 Growth factor receptor bound protein 2 1.16  0.4897   0.47  0.0207   0.37  0.0245   NM_030846.2 
22276618 Grip1 Glutamate receptor interacting protein 1 1.63  0.1956   1.92  0.2164   4.66  0.0000   NM_032069.1 
21999055 Igf1 Insulin-like growth factor 1 0.53  0.3679   0.37  0.2397   0.29  0.0368   NM_178866.2 
21698275 Il1b Interleukin 1 beta 2.67  0.1913   5.75  0.0217   1.90  0.1502   NM_031512.1 
21788366 Lect2 Leukocyte cell-derived chemotaxin 2 0.75  0.4936   0.16  0.0065   2.32  0.0009   XM_341486 
21243387 Lgals1 Lectin, galactose binding, soluble 1 0.80  0.6196   1.85  0.1189   2.40  0.0046   NM_019904.1 
21739265 Lgals3 Lectin, galactose binding, soluble 3 0.91  0.5875   1.97  0.0679   3.05  0.0321   NM_031832.1 
20916699 Mia2 Melanoma inhibitory activity 2 1.29  0.4184   0.42  0.0261   1.22  0.6230   XM_343068 
21951725 Nrg1 Neuregulin 1 1.63  0.2596   2.63  0.1390   0.13  0.0006   NM_031588.1 
21435765 Numb Numb gene homolog (Drosophila) 1.01  0.9668   0.37  0.0043   0.47  0.1130   NM_133287.1 
20878482 Pdgfa Platelet derived growth factor, alpha 0.75  0.1553   2.84  0.0082   1.59  0.0998   NM_012801.1 
20800589 Pdgfc 
Platelet-derived growth factor, C 
polypeptide 
2.53  0.0370   0.25  0.0069   0.90  0.7311   NM_031317.1 
21861133 Pf4 Platelet factor 4 0.70  0.3276   1.05  0.8315   2.59  0.0041   NM_001007729.1 
22197072 Plcl1 Phospholipase C-like 1 0.88  0.7009   0.12  0.0184   0.58  0.1968   NM_053456.1 
21720242 Ppp1r1a 
Protein phosphatase 1, regulatory (inhibitor) 
subunit 1A 
0.64  0.4995   0.13  0.1390   0.13  0.0304   NM_022676.3 
21554485 Psmc Pre-sialomucin complex 0.95  0.8944   1.37  0.1147   0.37  0.0084   XM_221384 
21725361 Pzp Pregnancy-zone protein 1.11  0.6942   0.08  0.0125   0.27  0.0353   NM_145779.1 
21579013 S100a11 
S100 calcium binding protein A11 
(calizzarin; predicted) 
0.92  0.6850   5.65  0.1203   4.49  0.0005   NM_001004095.1 
21687629 Skb1 
SKB1 homolog (Schizosaccharomyces 
pombe) (predicted) 
0.94  0.6836   2.10  0.0104   1.37  0.4582   XM_344405 
21897732 Stambp Associated molecule with the SH3 domain 1.17  0.5004   0.59  0.0806   0.49  0.0111   NM_138531.2 
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of signal-transducing adaptor molecule 
22350958 Tgfb2 Transforming growth factor, beta 2 0.88  0.2299   0.39  0.0257   1.35  0.5971   NM_031131.1 
21911962 Tgfbi Transforming growth factor, beta induced 0.59  0.5430   0.32  0.2984   0.21  0.0338   XM_573983 
21715280 Traf3 
TNF receptor-associated factor 3 
(predicted) 
0.99  0.9624   0.52  0.0157   0.49  0.0230   NM_001108724.1 
22166383 Trip10 Thyroid hormone receptor interactor 10 2.11  0.1552   3.82  0.0243   1.92  0.2074   XM_579584 
20717612 Tspan5 Tetraspanin 5 1.34  0.5546   0.16  0.0331   0.23  0.0199   NM_001004090.2 
21728398 Vgf VGF nerve growth factor inducible 0.71  0.4607   2.77  0.0184   1.66  0.4020   NM_030997.1 
21940318 Wisp1 
WNT1 inducible signaling pathway protein 
1 
0.47  0.1464   0.72  0.5068   3.28  0.0104   NM_031716.1 








 1.29  0.0255   0.32  0.0007   0.61  0.1281   XM_575419 
21901355   1.36  0.2174   3.86  0.0386   3.89  0.0003    
20901294   1.92  0.0193   0.39  0.0095   3.60  0.0024    
21070158   0.95  0.6891   1.06  0.6784   2.10  0.0458    
Proximal tubules and whole kidney samples were obtained from cisplatin-treated rats 2 days after cisplatin administration and microarray analyses were performed. 
Focusing on the signaling molecules, we determined the mRNA expression level ratio between cisplatin-treated and sham-treated rats and calculated P values with 
1-way analysis of variance. P < 0.05 was considered statistically significant. Bold type indicates the genes that changed more than 2-fold, with a P value of <0.05. 
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Figure 1. Time-dependent changes in renal function and histology of rats treated 
with 5 mg/kg cisplatin. The changes in creatinine clearance (Ccr), blood urea nitrogen 
(BUN), urinary excretion of albumin, and urinary N-acetyl--D-glucosaminidase (NAG) 
activity 1, 2, 4, and 7 days after cisplatin administration are shown (a). Histological 
analyses of the kidneys are also shown (b). *, glomeruli. Data are expressed as means ± 
standard error (S.E.) of 6 rats. Multiple comparisons were performed with Dunnett’s 
2-tailed test after 1-way analysis of variance (ANOVA). * P < 0.05, **P < 0.01, 
significantly different from the value on day 0. 
 
Figure 2. Cytokine and chemokine expression profiles of rats treated with 5 mg/kg 
cisplatin. Interleukin (IL)-1beta (a), chemokine (C-C motif) ligand (CCL) 2 (b), 
CCL20 (c), chemokine (C-X-C motif) ligand (CXCL) 1 (d), and CXCL10 (e) mRNA 
levels were examined. Whole-kidney total RNA was extracted from rats 1, 2, 4, and 7 
days after cisplatin treatment and reverse-transcribed to complementary DNA (cDNA). 
Real-time PCR analysis was performed using these cDNAs. 
Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA was used as an internal 
control. Data are expressed as means ± S.E. of 6 rats. Multiple comparisons were 
performed with Dunnett’s 2-tailed test after 1-way ANOVA. *P < 0.05, **P < 0.01, 
significantly different from the value on day 0. 
 
Figure 3. Comparison of CCL2 and kidney injury molecule-1 (Kim-1) expression 
in the kidney. (a) and (b), Total RNA was extracted from isolated proximal tubules 
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(open circles) and whole kidneys (closed circles) of rats treated with 5 mg/kg cisplatin. 
This RNA was reverse-transcribed to yield cDNA. Real-time polymerase chain reaction 
analysis of CCL2 (a) and Kim-1 (b) was performed using these cDNAs. GAPDH 
mRNA was used as an internal control. Ratio to day 0 was calculated, and data are 
expressed as means ± S.E. of 3–5 rats. Multiple comparisons were performed with 
Dunnett’s 2-tailed test after 1-way ANOVA. *P < 0.05, **P < 0.01, significantly 
different from the value at day 0. (c) and (d), Lysate samples were prepared from whole 
kidneys of rats treated with 5 mg/kg cisplatin. CCL2 concentrations were measured 
using enzyme-linked immunosorbent assay (ELISA) kits (c), and Kim-1 levels were 
determined with microsphere-based Luminex xMAP technology developed in the 
Vaidya/Bonventre laboratory [14, 15] (d). Multiple comparisons were performed with 
Dunnett’s two-tailed test after one-way ANOVA. Data are expressed as means ± SE of 
5 rats. *P < 0.05, **P < 0.01, and ***P < 0.001, significantly different from the value 
on day 0.  
 
Figure 4. Immunofluorescence analysis of CCL2 in rats treated with cisplatin. Rats 
treated with 5 mg/kg cisplatin were used. Kidneys were perfused, fixed with 4% 
paraformaldehyde, and embedded. The sections (5 m) were stained with an antibody 
specific for CCL2 (red), phalloidin (green), and 4′,6-diamidino-2-phenylindole (DAPI; 
blue). Scale bar, 100 m. The solid and dotted frames indicate magnifications of the 
cortex and medullary regions, respectively. Magnification: left panels, ×40; middle and 
right panels, ×400.  
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Figure 5. Immunofluorescence analysis of Kim-1 in rats treated with cisplatin. Rats 
treated with 5 mg/kg cisplatin were used. The kidneys were perfused, fixed with 4% 
paraformaldehyde, and embedded. The sections (5 m) were stained with an antibody 
specific for Kim-1 (red), phalloidin (green), and DAPI (blue). Scale bar, 100 m. The 
solid and dotted frames indicate magnifications of the cortex and medullary regions, 
respectively. Magnification: left panels, ×40; middle and right panels, ×400. 
 
Figure 6. Immunofluorescence analysis of IL-1beta (a), CCL20 (b), CXCL1 (c), and 
CXCL10 (d) in rats treated with cisplatin. Rats treated with 5 mg/kg cisplatin were used. 
The kidneys were perfused, fixed with 4% paraformaldehyde, and embedded. The sections (5 
µm) were stained with antibodies specific for IL-1beta, CCL20, CXCL1, or CXCL10. Red 
signals for each section were merged with green signals for phalloidin and with blue signals for 
DAPI. Scale bar, 100 µm. The solid frame indicates the magnification region. Magnification, 
×400. 
 
Figure 7. Measuring urinary and plasma CCL2 and urinary Kim-1 in rats treated with 5 
mg/kg cisplatin. CCL2 concentrations in bladder urine (open circles) and plasma (closed 
circles) in rats given 5 mg/kg cisplatin were measured using enzyme-linked immunosorbent 
assay (ELISA) kits (a). Kim-1 urinary levels were determined with microsphere-based 
Luminex xMAP technology developed in the Vaidya/Bonventre laboratory [14, 15] (b). 
Concentrations of urinary CCL2 and Kim-1 were normalized to urinary creatinine 
concentration. Plasma creatinine (open circles) and blood urea nitrogen (closed circles) levels 
in rats after administration of 5 mg/kg cisplatin are shown (c). Multiple comparisons were 
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performed with Dunnett’s 2-tailed test after 1-way ANOVA. Data are expressed as means ± 
S.E. of 5–7 rats. **P < 0.01, significantly different from the value on day 0. 
 
Figure 8. Measuring urinary and plasma CCL2 and urinary Kim-1 in nephrectomized 
rats treated with 2 mg/kg cisplatin. CCL2 concentrations in bladder urine (a) or plasma (b) in 
nephrectomized rats given saline (vehicle, open circles) or 2 mg/kg cisplatin (closed circles) 
were measured using ELISA kits. Kim-1 urinary levels in nephrectomized rats given saline 
(vehicle, open circles) or 2 mg/kg cisplatin (closed circles) were determined with 
microsphere-based Luminex xMAP technology developed in the Vaidya/Bonventre laboratory 
[14, 15] (c). Concentrations of urinary CCL2 and KIM-1 were normalized to urinary creatinine 
concentration. Plasma creatinine (open circles) and blood urea nitrogen levels (closed circles) 
in nephrectomized rats after administration of corn oil (vehicle, open circle) or 2 mg/kg 
cisplatin (closed circle) are shown (d). Multiple comparisons were performed with Dunnett’s 
2-tailed test after 1-way ANOVA. Data are expressed as means ± S.E. of 8 rats. **P < 0.01, 
significantly different from the value on day 0. 
Figure 1 
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Figure 6 (Continued) 
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